Failure of Curettage and Electrodesiccation for Removal of Basal Cell Carcinoma

d'Aubermont, Peter C. Suhge

doi:10.1001/archderm.1984.01650470062014

Cited by 40 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[11][12][13][14][15] There needs to be a greater availability of micrographic surgery for patients with recurrent tumours in the U.K. Furthermore, onethird of these recurrent tumours were treated by nonexcisional methods, despite the very high failure rates observed in these circumstances.…”

Section: Discussionmentioning

confidence: 99%

Treatment of basal cell carcinoma by dermatologists in the United Kingdom

et al. 1995

View full text Add to dashboard Cite

Details of presentation and treatment were obtained prospectively by questionnaire for 1366 patients with basal cell carcinoma, first attending under the care of 166 consultant dermatologists in the U.K., during a 2-week period. One thousand five hundred and ninety-seven tumours were reported in these patients (median age 71 years). Most were situated on the head and neck, and their median size was 9 mm. Excision was the most common treatment used in 58% of tumours, curettage and cautery was used in 24%, cryotherapy in 8%, and radiotherapy in 8%. On average, one in four tumours were referred to other specialists for treatment (range 0-70%). Very few patients (2%) were referred to a combined dermatology/radiotherapy/plastic surgery clinic, calling into question its value and availability. There was considerable variation in practices between dermatologists, demonstrating a clear need for individual, local audit of the management of this common dermatological problem. The data collected in this study form a suitable measure with which local performance may be compared.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of basal cell carcinoma by dermatologists in the United Kingdom

et al. 1995

View full text Add to dashboard Cite

show abstract

“…Residual tumour can be found if wounds created after curettage and electrodesiccation are immediately re-excised, and they are much more frequently found on head and neck (47%) than the trunk or limbs (8.3%) [91]. Overall 5-year recurrence rates for primary tumours treated with this technique vary from 3.3% in low-risk sites to 18.8% in high-risk ones [62,92].…”

Section: Curettage and Electrodesiccation/cauterymentioning

confidence: 99%

Update of the European guidelines for basal cell carcinoma management

Trakatelli¹,

Morton²,

Nagore³

et al. 2014

European Journal of Dermatology

199

197

View full text Add to dashboard Cite

Background European guidelines for the management of basal cell carcinoma (BCC) prepared by the former BCC subcommittee of the Guidelines Committee of the European Dermatology Forum (EDF) were published in 2006. Objectives To present updated guidelines that include consensual expert definitions on various BCC types, prognosis and risk factors for BCC as well as review recommendations for diagnosis and treatment reflecting current published evidence. Methods These guidelines (S1 type) were prepared by the new BCC subgroup of the European Dermatology Forum (EDF)'s Guidelines Committee through extensive literature review (up to 2012) and expert experience; they were extensively discussed within the EDF subcommittee and approved by peer reviewers of the EDF. Results BCC is a common tumour with an incidence rising worldwide. Three major clinical types of BCC are recognized: nodular, superficial and morpheaform. Four histological subtypes are defined: superficial, nodular, infiltrative and morpheaform. On the basis of the risk of relapse, three prognosis groups have been identified: high, intermediate and low risk. According to these classifications and evidence-based evaluation of the therapeutic strategies available, a decision tree is proposed for the management of BCCs. Conclusions. The guidelines offer a useful tool that will help dermatologists to select the most appropriate treatment for individual patients.

show abstract

“…In a study of 69 C&C wounds that were immediately re‐excised using MMS, residual tumour was found in 33% of cases overall, with striking differences seen in different body sites (47% of head and neck sites and 8·3% of trunk and limb sites contained residual BCC) 102 . This may be one reason why C&C is generally less successful in the treatment of facial lesions.…”

Section: Destructive Techniques: Surgicalmentioning

confidence: 99%

Guidelines for the management of basal cell carcinoma

Telfer¹,

Colver²,

Morton³

2008

Br J Dermatol

723

452

View full text Add to dashboard Cite

Summary This article represents a planned regular updating of the previous British Association of Dermatologists guidelines for the management of basal cell carcinoma. These guidelines present evidence‐based guidance for treatment, with identification of the strength of evidence available at the time of preparation of the guidelines, and a brief overview of epidemiological aspects, diagnosis and investigation.

show abstract

Failure of Curettage and Electrodesiccation for Removal of Basal Cell Carcinoma

Cited by 40 publications

References 27 publications

Treatment of basal cell carcinoma by dermatologists in the United Kingdom

Treatment of basal cell carcinoma by dermatologists in the United Kingdom

Update of the European guidelines for basal cell carcinoma management

Guidelines for the management of basal cell carcinoma

Contact Info

Product

Resources

About